Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs... Show more
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RDIV | 58.91 | 0.56 | +0.96% |
| Invesco S&P Ultra Dividend Revenue ETF | |||
| ROKT | 112.22 | 0.39 | +0.35% |
| Stt Strt® SPDR® S&PKenshoFnlFrntrsETF | |||
| IFLN | 18.26 | 0.02 | +0.11% |
| Invesco Bloomberg Enh Flln Angls ETF | |||
| APRJ | 25.10 | N/A | N/A |
| Innovator Premium Income 30 Bar ETF -Apr | |||
| FUTG | 3.56 | -0.02 | -0.61% |
| Leverage Shares 2X Long Futu Daily ETF | |||
A.I.dvisor indicates that over the last year, CAPR has been loosely correlated with VRAX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CAPR jumps, then VRAX could also see price increases.
| Ticker / NAME | Correlation To CAPR | 1D Price Change % | ||
|---|---|---|---|---|
| CAPR | 100% | +3.02% | ||
| VRAX - CAPR | 36% Loosely correlated | +3.56% | ||
| WVE - CAPR | 33% Loosely correlated | -3.36% | ||
| KRRO - CAPR | 33% Poorly correlated | -12.42% | ||
| MDGL - CAPR | 30% Poorly correlated | +0.79% | ||
| CORT - CAPR | 30% Poorly correlated | +3.91% | ||
More | ||||
The RSI Indicator for CAPR moved out of oversold territory on June 12, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In of the 29 cases the stock moved higher. This puts the odds of a move higher at .
The Momentum Indicator moved above the 0 level on June 17, 2026. You may want to consider a long position or call options on CAPR as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CAPR just turned positive on June 17, 2026. Looking at past instances where CAPR's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
CAPR moved above its 50-day moving average on June 25, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CAPR broke above its upper Bollinger Band on June 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CAPR entered a downward trend on June 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.098) is normal, around the industry mean (20.978). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). CAPR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (125.000) is also within normal values, averaging (367.072).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.